Zimmer Biomet Holdings Inc (ZBH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zimmer Biomet Holdings Inc (ZBH) has a cash flow conversion efficiency ratio of 0.033x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($418.70 Million) by net assets ($12.77 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Zimmer Biomet Holdings Inc market cap and net worth for the company's overall valuation and market capitalisation.
Zimmer Biomet Holdings Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Zimmer Biomet Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Zimmer Biomet Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zimmer Biomet Holdings Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Zimmer Biomet Holdings Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Banco Bradesco S/A ADR
NYSE:BBDO
|
0.432x |
|
Avic Shenyang Aircraft Co Ltd
SHG:600760
|
-0.203x |
|
Kasikornbank Public Company Limited
BK:KBANK
|
0.054x |
|
China Minsheng Banking Corp Ltd
SHG:600016
|
0.014x |
|
Northern Star Resources Limited
F:NS7
|
0.030x |
|
SS&C Technologies Holdings Inc
NASDAQ:SSNC
|
0.062x |
|
KNORR-BREMS. UNSP.ADRS1/4
F:KBXA
|
0.101x |
|
Evergy, Inc.
NASDAQ:EVRG
|
0.036x |
Annual Cash Flow Conversion Efficiency for Zimmer Biomet Holdings Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Zimmer Biomet Holdings Inc from 1999 to 2024. View latest Zimmer Biomet Holdings Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $12.48 Billion | $1.50 Billion | 0.120x | -5.11% |
| 2023-12-31 | $12.49 Billion | $1.58 Billion | 0.127x | +18.56% |
| 2022-12-31 | $12.03 Billion | $1.28 Billion | 0.107x | -9.75% |
| 2021-12-31 | $12.67 Billion | $1.50 Billion | 0.118x | +19.88% |
| 2020-12-31 | $12.20 Billion | $1.20 Billion | 0.099x | -22.84% |
| 2019-12-31 | $12.39 Billion | $1.59 Billion | 0.128x | -17.43% |
| 2018-12-31 | $11.28 Billion | $1.75 Billion | 0.155x | +14.93% |
| 2017-12-31 | $11.74 Billion | $1.58 Billion | 0.135x | -20.12% |
| 2016-12-31 | $9.67 Billion | $1.63 Billion | 0.169x | +94.92% |
| 2015-12-31 | $9.81 Billion | $849.80 Million | 0.087x | -46.74% |
| 2014-12-31 | $6.52 Billion | $1.06 Billion | 0.163x | +6.36% |
| 2013-12-31 | $6.30 Billion | $963.10 Million | 0.153x | -22.15% |
| 2012-12-31 | $5.87 Billion | $1.15 Billion | 0.196x | -7.99% |
| 2011-12-31 | $5.51 Billion | $1.18 Billion | 0.213x | +3.20% |
| 2010-12-31 | $5.77 Billion | $1.19 Billion | 0.207x | +4.35% |
| 2009-12-31 | $5.64 Billion | $1.12 Billion | 0.198x | +7.94% |
| 2008-12-31 | $5.65 Billion | $1.04 Billion | 0.184x | -7.68% |
| 2007-12-31 | $5.45 Billion | $1.08 Billion | 0.199x | -5.91% |
| 2006-12-31 | $4.92 Billion | $1.04 Billion | 0.211x | +12.77% |
| 2005-12-31 | $4.69 Billion | $878.20 Million | 0.187x | -14.13% |
| 2004-12-31 | $3.95 Billion | $862.20 Million | 0.218x | +38.99% |
| 2003-12-31 | $3.15 Billion | $494.80 Million | 0.157x | -73.87% |
| 2002-12-31 | $366.30 Million | $220.20 Million | 0.601x | -72.46% |
| 2001-12-31 | $78.70 Million | $171.80 Million | 2.183x | +145.16% |
| 2000-12-31 | $261.00 Million | $232.40 Million | 0.890x | +93.42% |
| 1999-12-31 | $391.00 Million | $180.00 Million | 0.460x | -- |
About Zimmer Biomet Holdings Inc
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skul… Read more